Sequenom shares should be bought at current levels, says Maxim

theflyonthewall.com

After Sequenom retained an investment bank to evaluate strategic alternatives for its Genetic Analysis segment, Maxim thinks divesting the unit could enable the company to raise capital. The company may need additional capital if it cannot reduce its cash burn rate, the firm added.

Rates

View Comments (0)